

# **The prognostic value of mean platelet volume in patients with coronary artery disease: a systematic review with meta-analyses.**

Akhmetzhan Galimzhanov,<sup>1</sup> Han Naung Tun,<sup>2</sup> Yersin Sabitov,<sup>3</sup> Francesco Perone,<sup>4</sup> Tigen Mustafa Kursat,<sup>5</sup> Erhan Tenekecioglu,<sup>6</sup> Mamas A Mamas<sup>7,8</sup>

1 - Department of propedeutics of internal disease, Semey Medical University, Semey, Kazakhstan; Keele Cardiovascular Research Group, Keele University, Stoke on Trent, Keele, United Kingdom.

2 - Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.

3 - Emergency Hospital, Semey, Kazakhstan.

4 - Cardiac Rehabilitation Unit, Rehabilitation Clinic “Villa delle Magnolie”, 81020 Castel Morrone, Caserta, Italy

5 - Faculty of Medicine, Department of Cardiology, Marmara University, Istanbul, Türkiye.

6 - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, Health Sciences University, Bursa, Türkiye; Department of Cardiology, Erasmus MC, Thorax Center, Erasmus University, Rotterdam, the Netherlands

7 - Keele Cardiovascular Research Group, Keele University, Stoke on Trent, Keele, United Kingdom.

8 - National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, UK

Short Title: Mean platelet volume in coronary artery disease.

Funding: None.

Disclosures: None

Corresponding author: Akhmetzhan Galimzhanov, [ahmed.galimzhan@gmail.com](mailto:ahmed.galimzhan@gmail.com), Department of propedeutics of internal disease, Semey Medical University, Semey, Kazakhstan. Twitter: @AkhmetzhanG

Total word count:

## Abstract

**Background:** Mean platelet volume (MPV) is a widely available laboratory index, however its prognostic significance in patients with coronary artery disease (CAD) is still unclear. We intended to investigate and pool the evidence on the prognostic utility of admission MPV in predicting clinical outcomes in patients with CAD.

**Methods:** PubMed, Web of Science, and Scopus were the major databases used for literature search. The risk of bias was assessed using the quality in prognostic factor studies. We used random-effects pairwise analysis with the Knapp and Hartung approach supported further with permutation tests and prediction intervals (PIs).

**Results:** We identified 52 studies with 47066 patients. A meta-analysis of 9 studies with 14,864 patients demonstrated that 1 femtoliter increase in MPV values was associated with a rise of 29% in the risk of long-term mortality (hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.22-1.37) in CAD as a whole. The results were further supported with PIs, permutation tests and leave-one-out sensitivity analyses. MPV also demonstrated its stable and significant prognostic utility in predicting long-term mortality as a linear variable in patients treated with percutaneous coronary intervention (PCI) and presented with acute coronary syndrome (ACS) (HR 1.29, 95% CI 1.20-1.39, and 1.29, 95% CI 1.19-1.39, respectively).

**Conclusion:** The meta-analysis found robust evidence on the link between admission MPV and the increased risk of long-term mortality in patients with CAD patients, as well as in patients who underwent PCI and patients presented with ACS.

**PROSPERO number:** [CRD42023495287](#)

**Keywords:** mean platelet volume; coronary artery disease, prognosis, mortality, systematic review.

## Introduction

Coronary artery disease (CAD) remains a significant contributor to cardiovascular mortality with the highest age-standardised rate 108.8 deaths per 100,000.<sup>1</sup> In this regard, it is crucial to improve prediction of adverse clinical events in this population. While numerous studies have investigated potential new biomarkers in cardiovascular medicine, only a few have translated into clinical practice due to factors such as cost, logistical challenges, a lack of understanding of complex atherosclerotic pathophysiology, and patient population heterogeneity.<sup>2</sup> Conversely, exploring the predictive value of readily available laboratory tests appears more feasible. For example, mean platelet volume (MPV) is a widely used, inexpensive parameter measured by routine automated analyzers.<sup>3</sup> Higher MPV indicates larger, younger platelets with a greater prothrombotic potential.<sup>4</sup> While several studies have been conducted to examine the prognostic value of MPV, there are inconsistent data around its utility in the prediction of ischemic outcomes.<sup>5-9</sup> Previously, we conducted a systematic review focused around the prognostic utility of MPV but only in acute coronary syndrome patients,<sup>10</sup> meanwhile another meta-analysis focused on only patients treated with percutaneous coronary intervention (PCI).<sup>11</sup> With new data available, we decided to update the systematic review and meta-analysis and broaden the population of interest. We therefore set out to investigate and compile the data that was currently available regarding the prognostic usefulness of admission MPV in predicting clinical outcomes in patients with CAD as a whole, as well as in the subpopulation of patients who were treated with PCI, had ACS, or had stable CAD.

## Methods

The prospectively registered protocol for the meta-analysis is available in PROSPERO with the number [CRD42023495287](#). The study followed the standards outlined in the Guide to systematic review and meta-analysis of prognostic factor studies and the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement.<sup>12,13</sup> PubMed, Web of Science, and Scopus were the major databases used for literature search. The search approach was developed utilising the following criteria: patient (coronary artery disease) - exposure (mean platelet volume) - outcome (mortality, major adverse cardiovascular events, etc.).<sup>13</sup> The full search strategy is described in the Supplementary Materials.

We explored clinical trial registries, high-impact journal websites, conference proceedings to retrieve additional publications. The citation-based tracking was based on references from the included publications and prior meta-analyses, as well as the CoCites tool, which ranks articles based on their co-citation rates (Supplementary Table ).<sup>14</sup> We used a specific ShinyApp tool to create a flow-diagram of the systematic review.<sup>15</sup>

## Screening

The inclusion criteria were studies that investigated the prognostic importance of admission MPV in all-comer CAD patients in prediction of clinical endpoints, such as mortality and major adverse cardiovascular events. We excluded articles dedicated to patients younger than 18 years, pregnant women, terminal liver and kidney diseases, and life expectancy less than 3 years. In terms of study design, we omitted case-control and

cross-sectional studies, case reports and series of cases, editorials, correspondence, brief reports, systematic and narrative reviews, and meta-analyses. The Rayyan web-based platform provided a machine-learning tool for semi-automated abstract selection to aid in the screening process.<sup>16</sup>

## Data extraction

The checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies—prognostic factors (CHARMS-PF) was applied to retrieve data from the original investigations.<sup>13,17</sup> The extracted data included information on study characteristics (publication year, country, study design, follow-up period), study population (inclusion criteria, sample size, mean age, gender, prevalence of risk factors, provided laboratory parameters), and effect estimates. If the original studies did not provide overall mean and standard deviations for the parameter of interest, these statistics were calculated indirectly from the reported data with the use of specific formulae.<sup>18,19</sup> A portion of the data was acquired directly from the primary investigation's authors.

The risk of bias was assessed using the quality in prognostic factor studies (QUIPS) tool, which evaluates six major domains: participation, attrition, prognostic factor measurement, confounding bias, outcome measurement, and analysis and reporting.<sup>20</sup> The screening, data extraction and the risk of bias assessment were conducted by several reviewers with any disagreement resolved via discussion with the whole team.

## Statistical analysis

We used random-effects pairwise analysis with both maximum (ML) and restricted maximum likelihood estimates (REML). To improve the interpretation of the results and reduce heterogeneity, statistical analyses were performed independently for studies with reported time-to-event and dichotomous effect estimates (hazard ratios (HRs) and odds ratios (ORs)), separately for studies that treated MPV as a linear or categorical variable, and separately for events that occurred at different times.<sup>13</sup> To mitigate the confounding bias, we conducted all statistical analyses only with adjusted summary effect estimates. We opted for the Knapp and Hartung approach in our meta-analyses to provide more reliable estimates.<sup>21–23</sup> While this method produces wider confidence intervals, it ensures a lower chance of falsely concluding an effect exists.<sup>21</sup> In order to further decrease type I error rates, we carried out permutation tests to support statistically significant results of the meta-analyses.<sup>24</sup> Prediction intervals (PIs) offer a valuable tool for meta-analysis, transcending the limitations of confidence intervals (CIs). While CIs focus on the precision of the pooled estimate, PIs capture the expected variability of true treatment effects across diverse settings, including those relevant to future patients encountered by clinicians.<sup>25,26</sup> Therefore, we also calculated PIs for meta-analyses with more than 5 studies and statistically significant results.<sup>26</sup>

The heterogeneity of the analyses were calculated with chi-squared,  $I^2$ , and tau-squared tests. To investigate how the prognostic significance of MPV varies depending on clinical scenarios, we performed subgroup analyses in different types of CAD. Furthermore, meta-regression analyses were carried out to investigate possible reasons for heterogeneity if the number of available studies was higher than 10. The publication bias was assessed both graphically (funnel plot asymmetry and trim and fill method) and statistically

with Begg's rank and Egger's regression tests. The validity of results were further approved by leave-one-out sensitivity analyses. All statistical analyses were implemented with the *metafor* statistical R package.<sup>27</sup> Given the potential influence of evidence certainty on interpretation and decision-making, the authors applied the GRADE approach and categorised the certainty of evidence as high, moderate, low, or very low.<sup>28</sup>

## Results

We identified 52 eligible studies with 47066 patients.<sup>5-9,29-75</sup> The flow-diagram of the search is presented in Figure 1. The search in additional databases is described in detail in Supplementary Table 1. The list of excluded studies is provided in Supplementary Table 2. The research originated primarily in East Asia (16 studies), followed by the Middle East (15), Europe (12), Latin America (6), South Asia (2) and Australia (1). While a total of 26 studies had a prospective design, another 26 studies were retrospective in nature. The baseline characteristics of the original studies showed a notable degree of heterogeneity. The mean age varied from 36.4 to 78.5 years. The prevalence of male sex ranged from 57% to 82%. Risk factor prevalence varied widely, with smoking ranging from 22 to 58%, diabetes mellitus from 26 to 100%, dyslipidemia from 53 to 90%, and hypertension from 59 to 80%. The detailed overview around study characteristics are found in Supplementary Table 3.

### The risk of bias assessment.

Detailed information on the risk of bias assessment is presented in Table 1. Generally speaking, a total of 13 studies did not possess high risk of bias features in any of the 6 examined domains.<sup>6,7,31,46,48,49,51,55,61,62,64,68,73</sup> Three research studies were deemed biased in four out of six categories,<sup>50,65,72</sup> whereas eighteen papers were deemed high-risk in just one category.<sup>5,8,9,29,30,33,35,38,40,41,45,52,53,56,59,60,67</sup> Four studies were classified as low-risk in four out of six domains,<sup>5,6,46,62</sup> meanwhile a total of 18 studies only showed low-risk qualities in one domain.<sup>31,32,34,36,41-43,49,50,52,59,63,66,69-72,75</sup> The review discovered significant flaws in some included studies. Concerns concerning bias arose from unclear participant selection processes, high dropout rates, and incomplete data reporting. Furthermore, potential measurement bias due to unreported analyzer details, uncontrolled confounding factors, and the possibility of selective reporting based on contradictions between methods and results were observed. Finally, because no studies were pre-registered. Determining the probability of selective reporting bias was challenging.

### The prognostic role of MPV in coronary artery disease

The results of the meta-analyses around the prognostic significance of MPV in all-comer CAD patients are presented in Figure 2 and Supplementary Figures S1-13. MPV as a linear variable was found to be an independent predictor of long-term mortality in CAD patients. A meta-analysis of 9 studies with 14,864 patients demonstrated that 1 femtoliter increase in MPV values was associated with a rise of 29% in the risk of follow-up mortality (HR 1.29, 95% CI 1.22-1.37). The results were further supported with calculating PIs (1.16-1.43), conducting permutation tests (1.29, 95% CI 1.21-1.39) and leave-one-out sensitivity analyses (Supplementary Table 4), and using REML as an estimator (1.29, 95% CI 1.22-1.37). The meta-analysis showed homogeneous results with the tau-squared statistics

approximating 0. The publication bias was not detected with Begg's rank and Egger's regression tests being non-significant (p values 0.11 and 0.26, respectively, Supplementary Figure 1).

The subgroup analysis did not detect any inconsistency of the results in the populations of stable CAD and ACS patients (P value for subgroup difference 0.98, Supplementary Table 5). The meta-regression analyses were non-informative due to the limited number of the included studies (Supplementary Table 6). The certainty of the evidence was graded as moderate.

The results for other outcomes were inconsistent. While some analyses showed a statistically significant connection, these results were not supported in the leave-one-out sensitivity analyses (MPV as a categorical variable for long-term mortality and analyses for in-hospital endpoints), calculation of prediction intervals (all in-hospital outcomes and long-term MACE), REML estimation (MPV as a categorical variable for long-term mortality), and publication bias assessment (for long-term and in-hospital MACE with MPV as a categorical variable, Supplementary Table 4 and Figures S1-13).

The subgroup analyses found statistically heterogeneous results in patients with ACS and stable CAD for long-term MACE with MPV being an independent predictor only in ACS subpopulation (p value for subgroup difference 0.03 and <0.001, Supplementary Table 5). Meanwhile, the meta-regression analysis also detected significant results of predictive importance of MPV in ACS patients compared to those in stable CAD patients in the analysis for long-term MACE. In addition, high heterogeneity in the meta-analyses could be explained with the prevalence of hypertension, smoking, and study design (Supplementary Table S6).

#### The prognostic role of MPV in patients treated with PCI

Concerning patients who underwent PCI, MPV also demonstrated its stable and significant prognostic utility in predicting long-term mortality as a linear variable with HR 1.29 [95% CI 1.20-1.39] (7 studies with 13,634 participants). The analyses with PIs (1.14-1.46), permutation tests (HR 1.29, 95% CI 1.20-1.39), REML estimators (1.30, 95% CI 1.20-1.40) were also conclusive (Figure 3). The heterogeneity was low with the tau-squared near 0. After eliminating one study at a time, the leave-one-out sensitivity analysis did not show any significant variation (Supplementary Table 4). No publication bias was identified with graphical assessment (Supplementary Figure S14), with Begg's rank (p value 0.38) and Egger's regression tests (p value 0.09). The evidence was regarded as moderate. As far as other endpoints, the analyses were nonsignificant or inconclusive with permutation tests, PIs, REML estimators, leave-one-out sensitivity analyses (Supplementary Figures 14-19). While the subgroup analyses did not find any inconsistency of the results in patients with stable CAD and ACS for long-term endpoints and MPV as a linear variable, the difference was significant for long-term MACE and MPV as a categorical variable. The meta-regression analyses were not informative due to the limited number of studies.

#### The prognostic role of MPV in ACS

The meta-analysis showed significant prognostic value of MPV as a continuous predictor for long-term mortality in ACS patients (HR 1.29, 95% CI 1.19-1.39) with the results being conclusive in leave-one-out sensitivity analyses (Supplementary Table 4),



estimation with PIs (1.12-1.48), permutation tests (HR 1.29, 95% CI 1.19-1.39), and REML statistics (1.29, 95% 1.19, 1.40). The results were homogeneous (tau squared statistics approximating 0). Although the number of included studies were low, publication bias was not detected with both graphical and statistical methods (p value 0.71 and 0.48, Supplementary Figure S20-21). The evidence was graded as moderate.

With respect to the other endpoints, the results were either nonsignificant or inconsistent with leave-one-out sensitivity analyses (for inhospital outcomes), estimation of PIs (long-term MACE and all inhospital outcomes), REML statistics (long-term mortality with MPV as a categorical variable). The funnel plots were asymmetrical that suggests the possibility of publication bias in the analyses for long-term and inhospital MACE (all p values <0.001, Supplementary Figures, 22-32). The subgroup and meta-regression analyses were noninformative.

### The prognostic role of MPV in stable CAD

In stable CAD patients, MPV as a linear variable predicted the occurrence of long-term mortality with HR 1.29 (95% CI 1.07-1.55) with consistent results from PIs and REML estimators (Supplementary Figure S33-35). However, these findings became nonsignificant after eliminating one study at a time (Supplementary Table S4). The analyses for long-term MACE did not reveal a prognostic value of MPV, however all analyses for stable CAD patients were limited with a low number of included studies. Hence, we regarded the certainty of the evidence as low.

## Discussion

This systematic review and meta-analysis found robust evidence that MPV, as a linear variable, was linked to the increased risk of long-term mortality in an all-comer population of CAD patients, patients treated with PCI, and patients with ACS. We revealed that one femtoliter increase in admission MPV values was associated with a rise of 29% in the risk of follow-up death in patients with CAD overall, as well as in PCI and ACS subpopulations. It is known that around 25% of statistically significant results from traditional meta-analyses are deemed to be nonsignificant after calculation with Knapp and Hartung adjustment.<sup>21</sup> However, since all of the CIs in our meta-analyses were determined using Knapp and Hartung adjustment and confirmed by permutation testing, the likelihood that these results are false-positive is relatively negligible. A prediction interval represents the degree of uncertainty we anticipate in the pooled estimates if a new study is added to the meta-analysis.<sup>76</sup> As a result, it is highly unlikely that the inclusion of new research from the same population will affect the conclusions of our meta-analyses since all of the PIs demonstrated the predictive value of MPV in predicting long-term mortality.

Although there was some data on the prognostic utility of MPV in predicting MACE, these results were not supported with calculation of PIs, REML statistics, and conducting permutation tests. It could be partially explained with the disparities in used definitions for MACE. This emphasises the need of utilising internationally standard terminology for study endpoints to make it easier to compare and pool results in systematic reviews and meta-analyses.<sup>77</sup> Moreover, we did not reveal conclusive findings regarding analyses with MPV treated as a categorical variable. Categorization of continuous exposures in

epidemiological studies are customary, however, it is proven to lead to loss of statistical power, useful information, and efficiency.<sup>78</sup> This could account for the discrepancy of results in analyses when MPV values were grouped by quantiles and tertiles.

There was a lack of studies investigating the nonlinear dose-response relationships between MPV and clinical outcomes in CAD patients. There is much data supporting the prognostic value of elevated MPV especially in acute thrombotic conditions. The high MPV values indicate the abundance of large-sized platelets known to be younger, more active with more prothrombotic potential.<sup>4</sup> However, the evidence on the unfavourable role of low MPV values for prognosis is also accumulating. The study led by Wada et al enrolled a large cohort of patients with stable CAD treated with elective PCI and found that a low MPV, but not a high MPV, was associated with the increased risk of ischemic outcomes even after adjustment with traditional risk factors (HR 1.16 per 1 femtoliter decrease, 95% CI 1.04–1.30; lowest versus highest MPV groups HR 1.43, 95% CI 1.10–1.86).<sup>7</sup> These findings highlight the possibility that distinct associations between MPV and clinical outcomes may result from differences in the pathophysiology of stable CAD and ACS. Our meta-regression and subgroup analyses also support this theory with a more significant prognostic value of MPV in ACS than in stable CAD. A study by Rief et al showed that low values of MPV were linked to the high risk of critical limb ischemia in peripheral artery disease patients (OR 0.84, 95% CI 0.75–0.94).<sup>79</sup> Another study revealed a positive association between a low MPV and poor survival in pancreatic cancer individuals.<sup>80</sup> Numerous studies found a negative correlation between MPV and autoimmune disease activity.<sup>81–83</sup> In Behçet's disease, for example, MPV decreased during disease exacerbation and rose during infection in same subjects.<sup>81</sup> These results emphasise the close interaction between thrombosis and inflammation by pointing to a relationship between low MPV values and chronic inflammation. It is believed that an increase in big platelet consumption at the sites of inflammation is the cause of a drop in MPV.<sup>3</sup> Large epidemiological studies are therefore desperately needed to examine the nonlinear relationship between MPV and clinical outcomes in patients with CAD across the entire MPV value range (Figure 4).

There is a lack of studies examining the additional values of MPV over prognostic scores in the prediction of adverse outcomes in patients with CAD. Taking into account the robust data on usefulness of MPV as a predictor and the availability of MPV in routine clinical practice, we believe that future studies should consider MPV as a candidate biomarker in decision-making models for CAD patients. A lack of laboratory standardisation was thought to hinder practical implementation of MPV as a biomarker in everyday clinical settings.<sup>3,84</sup> Although we did not reveal any impact of vendors of automated analysers on the prognostic utility of MPV for long-term mortality in the meta-regression analyses, it is necessary to improve standardisation in the measurement of MPV. However, modern machine learning techniques can integrate multidimensional data, such as MPV values, analyzer vendor, in vitro anticoagulant used, time lag after sampling, flow cytometry method, and more. These techniques can create sophisticated prediction and decision-making models that are challenging to derive using traditional statistics. This is especially valid in the age of artificial intelligence (Figure 4).

Our systematic review has several limitations that are mainly due to limitations of the primary investigations. The retrospective design of half of the included studies points to the



possibility of selection and recall bias in the review. Furthermore, a paucity of published data made it impossible to conduct meta-analyses for myocardial infarction, stent thrombosis, target vessel revascularization, stroke, heart failure, major bleeding. In addition, the observational nature of the primary studies justifies the only associative link between MPV and mortality in CAD patients. Despite extracting only adjusted statistics from the primary studies, the risk of confounding bias could not be excluded. Future Mendelian randomisation studies would be of great interest to determine the causal relationship between genetically determined MPV and the risk of atherosclerosis.

## **Conclusion**

The current systematic review and meta-analysis found robust evidence on the link between admission MPV and the increased risk of long-term mortality in overall CAD patients, as well as in patients who underwent PCI and patients presented with ACS. Our meta-analysis showed that one femtoliter increase in MPV was associated with a rise of 29% in the risk of long-term mortality in the CAD population. Further studies are needed to investigate dose-response relationships and value of MPV in clinical decision making.

## References

1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. *J Am Coll Cardiol*. 2022;80: 2361–2371.
2. Elliott P, Cowie MR, Franke J, Ziegler A, Antoniadou C, Bax J, et al. Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table. *Cardiovasc Res*. 2021;117: 1248–1256.
3. Gasparian AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? *Curr Pharm Des*. 2011;17: 47–58.
4. Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA. The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. *Nat Rev Cardiol*. 2012;9: 658–670.
5. Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol*. 2005;46: 284–290.
6. Taglieri N, Saia F, Rapezzi C, Marrozzini C, Bacchi Reggiani ML, Palmerini T, et al. Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. *Thromb Haemost*. 2011;106: 132–140.
7. Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S, et al. Mean platelet volume and long-term cardiovascular outcomes in patients with stable coronary artery disease. *Atherosclerosis*. 2018;277: 108–112.
8. Eisen A, Bental T, Assali A, Kornowski R, Lev EI. Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention. *J Thromb Thrombolysis*. 2013;36: 469–474.
9. Estévez-Loureiro R, Salgado-Fernández J, Marzoa-Rivas R, Barge-Caballero E, Pérez-Pérez A, Noriega-Concepción V, et al. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Thromb Res*. 2009;124: 536–540.
10. Galimzhanov A, Tenekecioglu E, Rustamova F, Tun HN, Mamas MA. The Prognostic Utility of Mean Platelet Volume in Patients With Acute Coronary Syndrome: A Systematic Review With Meta-Analyses. *Angiology*. 2022;73: 734–743.
11. Chen Z, Li N, Wang J, Li C, He S, Zhou X, et al. Association between mean platelet volume and major adverse cardiac events in percutaneous coronary interventions: a systematic review and meta-analysis. *Coron Artery Dis*. 2020;31: 722–732.
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The

- PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372: n71.
13. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. *BMJ*. 2019;364: k4597.
  14. Janssens ACJW, Gwinn M, Brockman JE, Powell K, Goodman M. Novel citation-based search method for scientific literature: a validation study. *BMC Med Res Methodol*. 2020;20: 25.
  15. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. : An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev*. 2022;18: e1230.
  16. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;5: 210.
  17. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med*. 2014;11: e1001744.
  18. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14: 135.
  19. Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023). Cochrane, 2023. Available from <https://training.cochrane.org/handbook/current/chapter-06#section-6-5-2>
  20. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. *Ann Intern Med*. 2013;158: 280–286.
  21. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol*. 2014;14: 25.
  22. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. *Stat Med*. 2001;20: 3875–3889.
  23. Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, et al. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. *Res Synth Methods*. 2019;10: 23–43.
  24. Follmann DA, Proschan MA. Valid inference in random effects meta-analysis. *Biometrics*. 1999;55: 732–737.
  25. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open*. 2016;6: e010247.

26. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc.* 2009;172: 137–159.
27. Viechtbauer W. Conducting Meta-Analyses in with the metafor Package. *J Stat Softw.* 2010;36. doi:10.18637/jss.v036.i03
28. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ.* 2008;336: 1106–1110.
29. Osuna PP, Ballesteros FN, Moríñigo Muñoz JL, Sánchez Fernández PL, Jiménez AA, Diego Domínguez M, et al. Influencia del volumen plaquetario medio sobre el pronóstico a corto plazo del infarto agudo de miocardio. *Rev Esp Cardiol.* 1998;51: 816–822.
30. Vakili H, Kowsari R, Namazi MH, et al. Could Mean Platelet Volume Predicts Impaired Reperfusion and In-Hospital Major Adverse Cardiovascular Event in Patients with Primary Percutaneous Coronary Intervention after ST-Elevation Myocardial In. *J Tehran Heart Cent.* 1;4(1):17-23.
31. Akpek M, Kaya MG, Uyarel H, Yarlioglues M, Kalay N, Gunebakmaz O, et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. *Atherosclerosis.* 2011;219: 334–341.
32. Goncalves SC, Labinaz M, Le May M, Glover C, Froeschl M, Marquis J-F, et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. *Am J Cardiol.* 2011;107: 204–209.
33. Tekbas E, Kara AF, Ariturk Z, Cil H, Islamoglu Y, Elbey MA, et al. Mean platelet volume in predicting short- and long-term morbidity and mortality in patients with or without ST-segment elevation myocardial infarction. *Scand J Clin Lab Invest.* 2011;71: 613–619.
34. Dogan A, Aksoy F, Icli A, Arslan A, Varol E, Uysal BA, et al. Mean platelet volume is associated with culprit lesion severity and cardiac events in acute coronary syndromes without ST elevation. *Blood Coagul Fibrinolysis.* 2012;23: 324–330.
35. López-Cuenca AA, Tello-Montoliu A, Roldán V, Pérez-Berbel P, Valdés M, Marín F. Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. *Angiology.* 2012;63: 241–244.
36. Vrsalovic M, Pintaric H, Babic Z, Pavlov M, Vrsalovic Presecki A, Getaldic B, et al. Impact of admission anemia, C-reactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. *Clin Biochem.* 2012;45: 1506–1509.
37. Akgul O, Uyarel H, Pusuroglu H, Gul M, Isiksacan N, Turen S, et al. Prognostic value of elevated mean platelet volume in patients undergoing primary angioplasty for ST-elevation myocardial infarction. *Acta Cardiol.* 2013;68: 307–314.
38. Fabregat-Andrés Ó, Cubillos A, Ferrando-Beltrán M, Bochard-Villanueva B, Estornell-Erill J, Fácila L, et al. Mean platelet volume is associated with infarct size and

microvascular obstruction estimated by cardiac magnetic resonance in ST segment elevation myocardial infarction. *Blood Coagul Fibrinolysis*. 2013;24: 424–427.

39. Nozari Y, Bahrehmand M, Hosseini SK, Mahmoodian M, Sharafi A. Mean Platelet Volume as a Predictor of One-Year Major Adverse Cardiac Events following Elective Percutaneous Coronary Interventions. *J Tehran Heart Cent*. 2014;9: 64–69.
40. Nozari Y, Parsa M, Jalali A, Ariannejad H, Shafiee A. Mean Platelet Volume and Major Adverse Cardiac Events following Percutaneous Coronary Intervention. *Arch Iran Med*. 2019;22: 198–203.
41. Unal EU, Ozen A, Kocabeyoglu S, Durukan AB, Tak S, Songur M, et al. Mean platelet volume may predict early clinical outcome after coronary artery bypass grafting. *J Cardiothorac Surg*. 2013;8: 91.
42. Bergoli LCC, Castanho ES, Gonçalves SC, Wainstein RV, Piardi D, Araújo G, et al. Volume Plaquetário Médio Como Preditor de Desfechos Cardiovasculares Maiores e Fluxo Coronariano Final em Pacientes Submetidos à Intervenção Coronária Percutânea Primária. *Rev Bras Cardiol Invasiva*. 2014;22: 240–244.
43. Lekston A, Hudzik B, Hawranek M, Szkodzinski J, Gorol J, Wilczek K, et al. Prognostic significance of mean platelet volume in diabetic patients with ST-elevation myocardial infarction. *J Diabetes Complications*. 2014;28: 652–657.
44. Choi S-W, Choi D-H, Kim H-W, Ku Y-H, Ha S-I, Park G. Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. *Platelets*. 2014;25: 322–327.
45. Liu Q, Wang T, Chen R, Liu C, Yue W, Hong J, et al. Mean platelet volume predicts left descending artery occlusion in patients with non-ST-elevation myocardial infarction. *Platelets*. 2014;25: 246–251.
46. Seo H-J, Ki Y-J, Han MA, Choi D-H, Ryu S-W. Brachial-ankle pulse wave velocity and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes in Korea: A comparable and additive study. *Platelets*. 2015;26: 665–671.
47. Seyyed-Mohammadzad MH, Eskandari R, Rezaei Y, Khademvatani K, Mehrpooya M, Rostamzadeh A, et al. Prognostic value of mean platelet volume in patients undergoing elective percutaneous coronary intervention. *Anatol J Cardiol*. 2015;15: 25–30.
48. Siller-Matula JM, Arbesu I, Jilma B, Maurer G, Lang IM, Mannhalter C. Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. *Thromb Haemost*. 2014;111: 1060–1066.
49. Wan Z-F, Zhou D, Xue J-H, Wu Y, Wang H, Zhao Y, et al. Combination of mean platelet volume and the GRACE risk score better predicts future cardiovascular events in patients with acute coronary syndrome. *Platelets*. 2014;25: 447–451.
50. Ghaffari S, Pourafkari L, Javadzadegan H, Masoumi N, Jafarabadi MA, Nader ND. Mean platelet volume is a predictor of ST resolution following thrombolysis in acute ST

elevation myocardial infarction. *Thromb Res.* 2015;136: 101–106.

51. Lai H-M, Xu R, Yang Y-N, Ma Y-T, Li X-M, Zhao Q, et al. Association of mean platelet volume with angiographic thrombus burden and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2015;85 Suppl 1: 724–733.
52. Chirino Navarta D, Monteros A, Trejo G, Baglioni F, Murua A, Leonardi M, et al. Mean platelet volume as prognostic marker in patients with acute coronary syndrome. *Rev Argent Cardiol.* 2015;83: 292–298.
53. Ranjith MP, DivyaRaj R, Mathew D, George B, Krishnan MN. Mean platelet volume and cardiovascular outcomes in acute myocardial infarction. *Heart Asia.* 2016;8: 16–20.
54. Lai H-M, Chen Q-J, Yang Y-N, Ma Y-T, Li X-M, Xu R, et al. Association of mean platelet volume with impaired myocardial reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Blood Coagul Fibrinolysis.* 2016;27: 5–12.
55. Wasilewski J, Desperak P, Hawranek M, Ciślak A, Osadnik T, Pyka Ł, et al. Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study. *Platelets.* 2016;27: 452–458.
56. Yu T, Dong Y, Sun Z, Sun Z. Comparison of prognostic significance of mean platelet volume/platelet count with GRACE for long-term prognosis in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. *Int J Cardiol.* 2017;228: 335–340.
57. Gina Yu, Je Sung You, Sung PC, Taeyoung K, Dongryul K, Sinae K, et al. Usefulness of Serial Measurement of the Platelet Volume Indices to Predict 30-day Mortality in Patients with ST Segment Elevation Myocardial Infarction. *J Korean Soc Emerg Med.* 2017; 28(5): 524-525.
58. Adam AM, Ali MA, Shah AA, Rizvi AH, Rehan A, Godil A, et al. Efficacy of hematological and coagulation parameters in the diagnosis and prognosis of patients with acute coronary syndrome. *J Tehran Heart Cent.* 2018;13: 115–125.
59. Machado GP, Araujo GN de, Carpes CK, Lech M, Mariani S, Valle FH, et al. Comparison of neutrophil-to-lymphocyte ratio and mean platelet volume in the prediction of adverse events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. *Atherosclerosis.* 2018;274: 212–217.
60. Monteiro Júnior JG de M, Torres D de OC, da Silva MCFC, Martins CM de H, da Silva IK, do Nascimento MEM, et al. Prognostic value of hematological parameters in patients with acute myocardial infarction: Intrahospital outcomes. *PLoS One.* 2018;13: e0194897.
61. Tian C, Song J, He D, Wu J, Sun Z, Sun Z. Predictive Value of Mean Platelet Volume/Platelet Count for Prognosis in Acute Myocardial Infarction. *Int Heart J.* 2018;59: 286–292.



62. Niu X, Liu G, Huo L, Zhang J, Bai M, Peng Y, et al. Risk stratification based on components of the complete blood count in patients with acute coronary syndrome: A classification and regression tree analysis. *Sci Rep*. 2018;8: 2838.
63. Çanga Y, Emre A, Karataş MB, Çalık AN, Yelgeç NS, Yıldız U, et al. Mean platelet volume predicts short-term prognosis in young patients with st-segment elevation myocardial infarction. *J Cardiovasc Emerg*. 2019;5: 50–58.
64. Chang H-Y, Hsu L-W, Lee C-H, Lin C-C, Huang C-W, Chen P-W, et al. Impact of Platelet Volume on the Clinical Outcomes of Patients with Acute Coronary Syndrome. *Acta Cardiol Sin*. 2019;35: 563–570.
65. Garlobo DLN, Dopico RR, Rivero BS, Lombillo CRP, Rodríguez LOC, Gómez OM. Volumen plaquetario medio y posible valor pronóstico en pacientes con infarto agudo de miocardio. *Revista Cubana de Medicina Militar*. 2019;48: 690–706.
66. Chirino Navarta D, Trejo G, Leonardi M, Crudo C, Arias M, Tellechea F, et al. Association between mean platelet volume and resistance to aspirin and P2Y12 receptor inhibitors in elderly patients with acute coronary syndrome. *Rev Argent Cardiol*. 2019;87: 258–264.
67. Şatiroğlu Ö, Durakoğlugil ME, Uydu HA, Duman H, Çetin M, Çiçek Y, et al. The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. *Cardiovasc Innov Appl*. 2019;4: 135–141.
68. Jiang P, Song Y, Xu J-J, Wang H-H, Jiang L, Zhao W, et al. Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention. *Cardiol J*. 2019;26: 138–146.
69. Vogiatzis I, Samaras A, Grigoriadis S, Sdogkos E, Koutsampasopoulos K, Bostanitis I. The Mean Platelet Volume in the Prognosis of Coronary Artery Disease Severity and Risk Stratification of Acute Coronary Syndromes. *Mediev Archaeol*. 2019;73: 76–80.
70. Chen X, Huang Z, Li G. Predictive Value of Neutrophil-to-lymphocyte Ratio Combined with Mean Platelet Volume for Nosocomial Major Adverse Cardiovascular Events in Patients with Acute STEMI after PCI. *Chinese General Practice*, 2020, 23(9): 1117-1126. DOI: 10.12114/j.issn.1007-9572.2019.00.676..
71. Chen X, Shao M, Zhang T, et al. Value of Hematological Parameters in Predicting Major Adverse Cardiovascular Events after PCI in Patients with Acute STEMI. *Chinese General Practice*, 2020, 23(27): 3389-3395. DOI: 10.12114/j.issn.1007-9572.2020.00.245.
72. Adali MK, Turkoz A, Yilmaz S. The prognostic value of the CHA2DS2-VASc score in coronary collateral circulation and long-term mortality in coronary artery disease. *Rev Assoc Med Bras*. 2022;68: 384–388.
73. Liang Q, Zhang Y, Liang J. Elevated Serum Total Bilirubin Might Indicate Poor Coronary Conditions for Unstable Angina Pectoris Patients beyond as a Cardiovascular Protector. *Cardiovasc Ther*. 2023;2023: 5532917.

74. Pedersen OB, Larsen SB, Kristensen SD, Hvas A-M, Grove EL. Immature platelets and cardiovascular events in patients with stable coronary artery disease. *Platelets*. 2023;34: 2217960.
75. Toprak K, Kaplangöray M, Memioğlu T, İnanir M, Omar B, Taşcanov MB, et al. HbA1c/C-peptide ratio is associated with angiographic thrombus burden and short-term mortality in patients presenting with ST-elevation myocardial infarction. *Blood Coagul Fibrinolysis*. 2023;34: 385–395.
76. Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. *Med Decis Making*. 2005;25: 646–654.
77. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Eur Heart J*. 2018;39: 2192–2207.
78. Altman DG. *Categorizing Continuous Variables*. Wiley StatsRef: Statistics Reference Online. Chichester, UK: John Wiley & Sons, Ltd; 2014.
79. Rief P, Raggam RB, Avian A, Hafner F, Sareban M, Wehrschoetz M, et al. Low mean platelet volume is associated with critical limb ischemia in peripheral arterial occlusive disease. *Sci Rep*. 2018;8: 6718.
80. Yagyu T, Saito H, Sakamoto T, Uchinaka E, Morimoto M, Hanaki T, et al. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. *BMC Surg*. 2021;21: 8.
81. Ryu HJ, Seo MR, Choi HJ, Ko K-P, Park PW, Baek HJ. Mean platelet volume as a marker for differentiating disease flare from infection in Behçet's disease. *Int J Rheum Dis*. 2018;21: 1640–1645.
82. Peng Y-F, Huang Y-X, Wei Y-S. Altered mean platelet volume in patients with polymyositis and its association with disease severity. *Braz J Med Biol Res*. 2016;49: e5168.
83. Delgado-García G, Galarza-Delgado DÁ, Colunga-Pedraza I, Borjas-Almaguer OD, Mandujano-Cruz I, Benavides-Salgado D, et al. Mean platelet volume is decreased in adults with active lupus disease. *Rev Bras Reumatol Engl Ed*. 2016;56: 504–508.
84. Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. *Platelets*. 2003. pp. 335–336.

## Figure legends

**Figure 1.** Flow diagram of the systematic search. MPV, mean platelet volume.

**Figure 2.** Meta-analysis for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates in patients with coronary artery disease. CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume; PI, prediction interval; RE, random effects; REML, restricted maximum likelihood.

**Figure 3.** Meta-analysis for long-term mortality with MPV treated as a categorical variable and hazard ratios as effect estimates in patients treated with percutaneous coronary intervention. CI, confidence interval; ML, maximum likelihood; MPV, mean platelet volume; PI, prediction interval; RE, random effects; REML, restricted maximum likelihood.

**Figure 4.** The limitations and future directions of research on mean platelet volume as a prognostic factor in coronary artery disease. ACS, acute coronary syndrome; CAD, coronary artery disease; ML, machine learning; MPV, mean platelet volume; PCI, percutaneous coronary intervention.

**Table 1. The risk of bias assessment.**

Study, year	Study Participation	Study Attrition	Prognostic Factor Measurement	Outcome Measurement	Study Confounding	Statistical Analysis and Reporting
Osuna, 1999	Low	High	Low	Moderate	Low	Moderate
Huzcek, 2005	Low	Low	Moderate	Low	Low	High
Estevez-Loureiro, 2009	Low	High	Moderate	Low	Low	Moderate
Vakili, 2009	High	Low	Moderate	Moderate	Low	Moderate
Akpek, 2011	Moderate	Low	Moderate	Moderate	Moderate	Moderate
Goncalves, 2011	Moderate	High	Moderate	Moderate	Low	High
Taglieri, 2011	Low	Moderate	Low	Low	Low	Moderate
Tekbas, 2011	Low	High	Moderate	Low	Low	Moderate
Dogan, 2012	Low	High	Moderate	Moderate	High	Moderate
Lopez-Cuenca, 2012	Moderate	High	Moderate	Moderate	Moderate	Moderate
Vrsalovic, 2012	High	High	Moderate	Low	High	Moderate
Eisen, 2013	Moderate	High	Low	Low	Low	Moderate
Akgul, 2013	Low	High	Moderate	Low	High	High
Fabregat Andreas, 2013	Low	High	Low	Moderate	Low	Moderate
Nozari, 2013	Moderate	Moderate	High	High	High	Moderate
Unal, 2013	Low	Moderate	Moderate	High	Moderate	Moderate
Bergoli 2014	High	Low	High	Moderate	High	Moderate
Lekston, 2014	High	High	Moderate	Low	Moderate	High
Choi, 2014	Moderate	High	Moderate	Moderate	High	Moderate
Liu, 2014	Low	Low	Moderate	Moderate	High	Moderate
Seo, 2014	Low	Low	Low	Low	Moderate	Moderate
Seyyed-Mohammadzad, 2014	Low	Low	High	High	Moderate	Moderate
Siller-Matula, 2014	Low	Moderate	Moderate	Low	Moderate	Moderate
Wan, 2014	Low	Moderate	Moderate	Moderate	Moderate	Moderate
Ghaffari, 2015	Low	High	High	Moderate	High	High
Lai, 2015	Low	Low	Moderate	Low	Moderate	Moderate
Navarta, 2015	Low	Moderate	Moderate	Moderate	High	Moderate
Ranjith, 2015	Low	Low	Moderate	Moderate	Low	High
Lai, 2016	High	Low	Low	Low	Moderate	Moderate

Wasilewski, 2016	Moderate	Low	Low	Low	Moderate	Moderate
Tongtong Yu, 2017	Low	High	Low	Moderate	Low	Moderate
Gina Yu, 2017	Low	High	Low	Low	High	Moderate
Adam, 2018	Low	High	Moderate	Low	High	Moderate
Machado, 2018	Low	Moderate	Moderate	Moderate	High	Moderate
Monteiro Júnior, 2018	Low	Low	Moderate	Low	High	Moderate
Tian, 2018	Low	Moderate	Low	Moderate	Moderate	Moderate
Niu, 2018	Low	Moderate	Low	Low	Low	Moderate
Wada, 2018	Low	Low	Moderate	Low	Moderate	Moderate
Çanga, 2019	Low	High	Moderate	Moderate	High	Moderate
Chang, 2019	Low	Low	Moderate	Moderate	Low	Moderate
Garlobo, 2019	High	High	High	High	Moderate	Moderate
Navarta, 2019	Low	High	Moderate	Moderate	High	Moderate
Nozari, 2019	High	Moderate	Moderate	Moderate	Moderate	Moderate
Şatiroğlu, 2019	Low	Low	Moderate	Low	High	Moderate
Jiang, 2019	Low	Moderate	Low	Moderate	Moderate	Moderate
Vogiatzis, 2019	High	Low	High	Moderate	High	Moderate
Xinsen, 2020	Low	High	High	Moderate	High	Moderate
Chen Xinsen, 2020	Low	High	High	Moderate	Moderate	Moderate
Adali, 2022	Low	High	High	High	Moderate	High
Liang, 2023	Low	Low	Moderate	Low	Moderate	Moderate
Pedersen, 2023	Low	Moderate	High	Low	Moderate	High
Toprak, 2023	Low	High	High	Moderate	Moderate	Moderate


The risk of bias assessment was performed according to the QUIPS tool. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280-286.

Identification of new studies via databases and registers


Identification


Screening

Included









# Mean platelet volume as a prognostic factor in coronary artery disease

## Limitations

Discrepancy in endpoint definitions

Lacking evidence in stable CAD


Lacking data on non-linear associations and value of low MPV

Lack of laboratory standardization

Non-inclusion of MPV in prognostic models

Lacking evidence on the causal link

There is a strong association between MPV and the risk of long-term mortality in CAD, ACS, and PCI



## Future directions

Use of standard endpoint definitions

More research on MPV in stable CAD

Dose-response studies on the link between MPV and outcomes

Use of unified laboratory standards

MPV in prognostic models, incl. ML

Mendelian randomisation research

# The prognostic value of mean platelet volume in patients with coronary artery disease - systematic review and meta-analysis



10,536 articles  
from 3 main  
databases





QUIPS tool for  
quality  
assessment



Knapp and Hartung  
and prediction  
intervals



Included 52  
studies,  
47066 patients



**1 fl increase in mean platelet volume values is associated with a rise of 29% in the risk of follow-up mortality in coronary artery disease**

**Mean platelet volume as a linear variable is an independent predictor of long-term mortality in CAD, ACS, and patients after PCI**